| Title |
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, September 2021
|
| DOI | 10.1158/1535-7163.mct-21-0273 |
| Pubmed ID | |
| Authors |
Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villaflor, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, John H. Strickler |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| Unknown | 5 | 56% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
| Science communicators (journalists, bloggers, editors) | 1 | 11% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 17% |
| Student > Bachelor | 3 | 13% |
| Student > Master | 2 | 8% |
| Other | 1 | 4% |
| Researcher | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 12 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 21% |
| Biochemistry, Genetics and Molecular Biology | 2 | 8% |
| Immunology and Microbiology | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 13 | 54% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2023.
All research outputs
#3,714,590
of 25,246,334 outputs
Outputs from Molecular Cancer Therapeutics
#574
of 4,072 outputs
Outputs of similar age
#80,575
of 423,805 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#8
of 51 outputs
Altmetric has tracked 25,246,334 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,072 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,805 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.